Aa
can i take harvoni if i have aschites and decompensated cirosis ?
can i take harvoni if i have aschites and decompensated cirosis ?
Ascitites is a symptom of decompensated cirrhosis. I have compensated cirrhosis with a small amount of ascities an edema. I treated with Harvoni for 24 weeks and Ribavirin which was added after I started for 15 of those 24 weeks.
I had only a few mild headaches and maybe a few extra aches and pains. Got a bit anemic from the ribavirin so had to dose reduce but that's about it. I was 24SVR weeks in October and am cured of hep c
Good luck to you
I had only a few mild headaches and maybe a few extra aches and pains. Got a bit anemic from the ribavirin so had to dose reduce but that's about it. I was 24SVR weeks in October and am cured of hep c
Good luck to you
There are no contraindications for Ascites with regards to taking Harvoni. It should not make your condition worse or affect it in any way.
It is a very well tolerated medication.
It is a very well tolerated medication.
Read the hcvguidelines There are situations where Harvoni can be used. But As mentioned only a medical professional perferably in a liver transport center should provide you with an answer after asscessing your current condition.
Best wishes for obtaining a successful outcome.
http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-decompensated-cirrhosis
Accessed December 16, 2015
Patients with HCV genotype 1 or 4 infection with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh [CTP] class B or C) should be referred to a medical practitioner with expertise in that condition (ideally in a liver transplant center).
Rating: Class I, Level C
Recommended regimens for patients with genotype 1 or 4 HCV infection with decompensated cirrhosis (moderate or severe hepatic impairment; CTP class B or C) who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma.
Daily daclatasvir (60 mg), sofosbuvir (400 mg), and low initial dose of RBV (600 mg, increased as tolerated) for 12 weeks is recommended for patients with HCV genotype 1 or 4 with decompensated cirrhosis.
Rating: Class II, Level A
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and low initial dose of RBV (600 mg, increased as tolerated) for 12 weeks is recommended for patients with HCV genotype 1 or 4 with decompensated cirrhosis.
Rating: Class IIb, Level C
Recommended regimen for patients with genotype 1 or 4 HCV infection with decompensated cirrhosis who are RBV intolerant or ineligible.
Daily daclatasvir (60 mg) and sofosbuvir (400 mg) for 24 weeks is recommended for patients with decompensated cirrhosis who are RBV intolerant or ineligible.
Rating: Class IIb, Level C,,
Recommended regimen patients with genotype 1 or 4 HCV infection with decompensated cirrhosis in whom prior sofosbuvir-based treatment has failed.
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and low initial dose of RBV (600 mg, increased as tolerated) for 24 weeks is recommended for patients with genotype 1 or 4 HCV infection with decompensated cirrhosis in whom prior sofosbuvir-based treatment has failed.
Rating: Class IIb, Level C
Best wishes for obtaining a successful outcome.
http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-decompensated-cirrhosis
Accessed December 16, 2015
Patients with HCV genotype 1 or 4 infection with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh [CTP] class B or C) should be referred to a medical practitioner with expertise in that condition (ideally in a liver transplant center).
Rating: Class I, Level C
Recommended regimens for patients with genotype 1 or 4 HCV infection with decompensated cirrhosis (moderate or severe hepatic impairment; CTP class B or C) who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma.
Daily daclatasvir (60 mg), sofosbuvir (400 mg), and low initial dose of RBV (600 mg, increased as tolerated) for 12 weeks is recommended for patients with HCV genotype 1 or 4 with decompensated cirrhosis.
Rating: Class II, Level A
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and low initial dose of RBV (600 mg, increased as tolerated) for 12 weeks is recommended for patients with HCV genotype 1 or 4 with decompensated cirrhosis.
Rating: Class IIb, Level C
Recommended regimen for patients with genotype 1 or 4 HCV infection with decompensated cirrhosis who are RBV intolerant or ineligible.
Daily daclatasvir (60 mg) and sofosbuvir (400 mg) for 24 weeks is recommended for patients with decompensated cirrhosis who are RBV intolerant or ineligible.
Rating: Class IIb, Level C,,
Recommended regimen patients with genotype 1 or 4 HCV infection with decompensated cirrhosis in whom prior sofosbuvir-based treatment has failed.
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and low initial dose of RBV (600 mg, increased as tolerated) for 24 weeks is recommended for patients with genotype 1 or 4 HCV infection with decompensated cirrhosis in whom prior sofosbuvir-based treatment has failed.
Rating: Class IIb, Level C
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
